BioLeaders "Ranked 9th in 'Asia-Pacific High Growth Companies 2020' by UK FT"

[Asia Economy Reporter Hyunseok Yoo] BioLeaders announced on the 22nd that it has been selected as one of the 'FT High-Growth Companies Asia-Pacific' by the Financial Times (FT), a world-renowned British economic newspaper.

In this selection, BioLeaders ranked 9th overall among 500 companies in the Asia-Pacific region and earned the top position in its industry category.

The Financial Times has been selecting and announcing high-growth companies based on criteria such as the compound annual growth rate (CAGR) and annual revenue since 2017.

Founded in 1999, BioLeaders is a specialized immuno-oncology treatment company with new drug platforms such as MucoMAX and HumaMAX. It is accelerating synergy creation with group affiliates including TCM Life Science, a company specializing in in vitro diagnostics selling COVID-19 test kits, and NextBT, a health functional food specialist.

The pipeline clinical trials are also progressing smoothly. Results for the Phase 2b clinical trial of the cervical precancer treatment (BLS-M07) and the Phase 1 clinical trial of the Duchenne muscular dystrophy treatment (BLS-M22) are scheduled for the 2nd to 3rd quarter of this year. In the Phase 2a trial, BLS-M07 showed nearly complete recovery in 75% of patients. A company representative stated, “It is meaningful to be selected as the number one high-growth company in the same industry by a globally reputable economic newspaper with objective indicators and credibility,” and added, “We will continue to strive to increase corporate value.”

This content was produced with the assistance of AI translation services.